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Mitogen-activated protein kinase (MAPK) cascades
are activated by diverse extracellular signals and par-
ticipate in the regulation of an array of cellular pro-
grams. In this study, we investigated the roles of MAPKs
in the induction of phase II detoxifying enzymes by
chemicals. Treatment of human hepatoma (HepG2) and
murine hepatoma (Hepa1c1c7) cells with tert-butylhyd-
roquinone (tBHQ) or sulforaphane (SUL), two potent
phase II enzyme inducers, stimulated the activity of ex-
tracellular signal-regulated protein kinase 2 (ERK2) but
not c-Jun N-terminal kinase 1. tBHQ and SUL also acti-
vated MAPK kinase. Inhibition of MAPK kinase with its
inhibitor, PD98059, abolished ERK2 activation and im-
paired the induction of quinone reductase, a phase II
detoxifying enzyme, and antioxidant response element
(ARE)-linked reporter gene by tBHQ and SUL. Overex-
pression of a dominant-negative mutant of ERK2 also
attenuated tBHQ and SUL induction of ARE reporter
gene activity. Interestingly, although expression of Ras
and its mutant forms showed distinct effects on basal
ARE reporter gene activity, they did not affect the acti-
vation of reporter gene by the inducers. Furthermore, a
dominant-negative mutant of Ras had little effect on
ERK2 activation by tBHQ and SUL, implicating a Ras-
independent mechanism. Indeed, both tBHQ and SUL
were able to stimulate Raf-1 kinase activity in vivo as
well as in vitro. Thus, our results indicate that the in-
duction of ARE-dependent phase II detoxifying enzymes
is mediated by a MAPK pathway, which may involve
direct activation of Raf-1 by the inducers.
Mitogen-activated protein kinases (MAPKs),1 which belong
to the superfamily of serine/threonine kinases, are evolution-
arily conserved in all eucaryotes and play a central role in
transducing various extracellular signals into the nuclei (1). A
typical MAPK cascade consists of three kinases: a MAPK ki-
nase kinase, which phosphorylates and activates a MAPK ki-
nase, which, in turn, phosphorylates and activates MAPK (2). A
well established MAPK pathway is the Ras-dependent activa-
tion of extracellular signal-regulated protein kinases (ERKs)
(3). In this pathway, activated Ras recruits Raf (a MAPK ki-
nase kinase) to the membrane, resulting in activation of Raf.
The activated Raf then phosphorylates and activates MEK (a
MAPK kinase), which directly activates ERK through dual
phosphorylation on threonyl and tyrosyl residues within the
tripeptide motif TEY. Parallel to ERK pathway, c-Jun N-ter-
minal kinase (JNK) is regulated by a distinct module consisting
of MEKK1/ASK/TAK-MKK4/MKK7-JNK (4), which is farther
regulated by the small GTPases, Rac1 or Cdc42 (5). ERK and
JNK are often responsive to different extracellular signals (6,
7). However, they can also be activated by the same stimuli
such as mitogenic signals, growth factors, oncogenic Ras (8, 9),
stress signals, UV radiation, and oxidative stress (10, 11). Once
activated, ERK and JNK can phosphorylate a number of cyto-
solic proteins and transcription factors such as c-Jun, ATF2,
and ternary complex factors, resulting in the enhancement of
their transcriptional activities and activation of dependent
genes (12). Considering the general involvement of MAPK
pathways in cellular responses to various stimuli, we examined
the roles of these kinases in the induction of phase II detoxify-
ing enzymes by chemicals.
Phase II detoxifying enzymes include NAD(P)H:quinone ox-
idoreductase/DT-diaphorase (QR), glutathione S-transferases
(GSTs), UDP-glucuronosyl transferases, and epoxide hydro-
lases. These enzymes are capable of converting the reactive
electrophiles to less toxic and more readily excretable products,
thus protecting cells against various chemical stresses and
carcinogenesis (13–15). Biochemical and genetic studies re-
vealed that the induction of phase II detoxifying enzymes by
various chemicals occurs at the transcriptional level and is
regulated by a cis-acting regulatory element, defined as anti-
oxidant responsive element (ARE) or electrophile-responsive
element. This regulatory element was first detected in the
59-flanking region of the rat and mouse GST Ya subunit gene
(16–18) and human QR genes (19, 20) and is also expected to be
present in the promoters of epoxide hydrolase and UDP-glucu-
ronosyl transferase genes. Because the ARE core sequence
(GTGACnnnGC) is similar to AP-1-binding site (TGACTCA), it
has been suggested that AP-1 may be the activator of ARE.
Indeed, the components of AP-1 complex, such as c-Jun and
c-Fos, are found to bind to ARE sequence, and overexpression of
c-Jun leads the induction of ARE-dependent genes (21–24).
However, several independent studies indicate that the major
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ARE-binding proteins that mediate the induction of detoxifying
enzymes may not be the AP-1 proteins (25–28). Although the
identity of ARE-binding proteins remains to be characterized,
activation of the ARE-protein complex by phase II enzyme
inducers is believed to be regulated by signal transducing ki-
nase cascades (29, 30). In this study, we identified ERK2 kinase
pathway to be involved in the ARE-mediated induction of phase
II detoxifying enzymes by tert-butylhydroquinone (tBHQ) and
sulforaphane (SUL). Furthermore, we showed that this induc-
tion may involve direct activation Raf-1 by the inducers, thus
implicating the existence of a novel Ras-independent pathway
for Raf-1 activation.
MATERIALS AND METHODS
Cell Culture, Antibodies, DNA Plasmids, and Chemicals—HepG2
and Hepa1c1c7 cell lines (obtained from American Type Culture Col-
lection, Manassas, VA) were cultured in minimum essential medium
supplemented with 10% fetal bovine serum, 2.2 g/liter sodium bicar-
bonate, 100 units/ml penicillin, and 100 mg/ml streptomycin. Cells were
normally starved overnight in serum-free medium before treatment,
unless otherwise indicated. Rabbit anti-ERK2 and anti-Raf-1 polyclonal
antibodies were purchased from Santa Cruz Biotechnology Inc. (Santa
Cruz, CA). Anti-HA monoclonal antibody (12CA5) was purchased from
Boeringer Mannheim. Rabbit anti-JNK1 antiserum (Ab101) was de-
scribed previously (31). GST-c-Jun (1–79)-expressing plasmid was
kindly provided by Dr. Karin (University of California, San Diego, CA).
GST-c-Jun fusion protein was purified from Escherichia coli lysates
with aid of glutathione-Sepharose beads (Amersham Pharmacia Bio-
tech). Construct pARE-CAT containing a single copy of 41-base pair rat
GST-Ya subunit ARE (59-GAGCTTGGAAATGGCATTGCTAATGGT-
GACAAAGCAACTTT) and a minimal GST-Ya promoter was a gift from
Dr. Rushmore (Merck Research Laboratory, West Point, PA). ARE-
luciferase reporter construct, pTI-ARE-luciferase, which contains a sin-
gle copy of 41-base pair mouse ARE (59-TAGCTTGGAAATGACATT-
GCTAATGGTGACAAAGCAACTTT) and minimal TATA-Inr promoter)
was obtained from Dr. Fahl (University of Wisconsin, Madison, WI).
pLNCAL7 expression constructs for HA-tagged ERK2(WT) and domi-
nant-negative mutant ERK2(KR) have been described previously (32).
pZIP retrovirus constructs of ras(WT), ras(61L), and ras(17N) were
constructed as described previously (33). The specific MEK-1 inhibitor
(PD98059) and the Raf-1 substrate (inactive MEK fusion protein) were
purchased from New England Biolabs Inc. (Beverly, MA). SUL was
purchased from LKT Laboratories (St. Paul, MN). tBHQ was purchased
from Aldrich. Myelin basic protein (MBP) was purchased from Sigma.
[g-32P]ATP (6,000 Ci/mmol) was purchased from NEN Life Science
Products.
Immunocomplex Kinase Assays of ERK2, JNK1, and Raf-1 Activi-
ties—After treatment with SUL or tBHQ (both agents were dissolved in
Me2SO), and cells were washed twice with ice-cold phosphate-buffered
saline and harvested in lysis buffer containing 10 mM Tris-HCl, pH 7.1,
50 mM NaCl, 50 mM NaF, 30 mM Na4P2O7, 100 mM Na3VO4, 2 mM
iodoacetatic acid, 5 mM zinc chloride, 1 mM phenylmethylsulfonyl fluo-
ride, and 0.5% Triton X-100. Cell lysates were homogenized by passing
through a 23-G needle three times and left on ice for 15 min. The
homogenates were then centrifuged at high speed for 15 min at 4 °C.
Endogenous ERK2, JNK1, or Raf-1 in the supernatants were immuno-
precipitated with the respective antibodies and assayed for kinase
activity by the method described previously (31). Briefly, following
immunoprecipitation, the immunocomplex was washed twice with lysis
buffer and twice with kinase assay buffer containing 20 mM HEPES, pH
7.9, 10 mM MgCl2, 2 mM MnCl2, 0.1 mM Na3VO4, 50 mM b-glycerophos-
phate, and 10 mM r-nitrophenyl phosphate. Kinase reaction was initi-
ated by resuspending the immunopreciptate in a 30-ml kinase assay
buffer supplemented with 2 mCi of [g-32P]ATP, 20 mM ATP, and 2 mg of
the indicated substrates. After incubation for 15 min in ERK and Raf-1
assays or for 30 min in JNK assay at 30 °C, the reaction was terminated
with Laemmli’s buffer. Samples were heated to 95 °C for 5 min and
analyzed by electrophoresis. The phosphorylated substrates were visu-
alized by autoradiography, and quantitated with a phosphorimager
(AMBIS, Inc., San Diego, CA).
MAPK Kinase Assay—After treatment, cell lysates were prepared as
described in immunocomplex kinase assays. Total activity of MAPK
kinase 1 and MAPK kinase 2 (MEK1/2) in cell lysates was determined
using an inactive p42MAPK mutant K52R as substrate as described
previously (34). Briefly, equal portions (about 2 mg of protein) of cell
lysates was incubated with 2.5 mg of K52R in a 30-ml kinase assay
buffer with addition of 2 mCi of [g-32P]ATP and 25 mM ATP. The kinase
reaction was terminated with Laemmli’s buffer 15 min after incubation
at 30 °C. Phosphorylated K52R was resolved on 10% SDS-polyacryl-
amide gels and visualized by autoradiography.
Transfection and Assays of Reporter Gene Activity—HepG2 cells were
plated in six-well plates 24 h before transfection at a density of 1.5 3
105 cells/well. Cells were transfected with different plasmids as indi-
cated in the figure legends using FuGENETM 6 (0.7 mg of DNA/ml of
reagent), according to the manufacturer’s protocol (Roche Molecular
Biochemicals). After overnight incubation with transfection mixture,
cells were cultured in fresh medium containing 0.5% fetal bovine serum
for 12 h prior to drug treatment. The b-galactosidase activity was
determined as described previously (35). For CAT activity assay, trans-
fected cells were washed twice with ice-cold phosphate-buffered saline
after drug treatment and harvested in lysis buffer provided by manu-
facturer (Promega, Madison, WI). 10 mg of protein, as determined by
Bradford assay (Bio-Rad), was incubated with reaction buffer for 60 min
at 37 °C. The acetylated products of [14C]chloramphenicol were sepa-
rated by TLC, visualized by autoradiography, and quantitated by Bio-
logical Image Analysis (AMBIS, Inc., San Diego, CA). All CAT activities
were normalized against b-galactosidase activity. Luciferase activity
was determined according to the protocol provided by manufacturer
(Promega). Briefly, after drug treatment, cells were washed twice with
ice-cold phosphate-buffered saline and harvested in reporter lysis
buffer. Following brief centrifugation (5 s) at high speed, the superna-
tant was transferred to a new tube, and 20 ml of cell lysate was assayed
for luciferase activity using a TD-20/20 luminometer (Turner Designs,
Sunnyvale, CA). Luciferase activity was normalized against b-galacto-
sidase activity yielding a final value of relative light units/b-galactosid-
ase units.
Quinone Reductase Activity Assay—After treatment, Hepa1c1c7 cells
were washed twice with ice-cold phosphate-buffered saline and har-
vested in a buffer containing 25 mM Tris-HCl, pH 7.4, and 125 mM
sucrose. Cell suspension was sonicated for 5 s and left on ice for 10 min.
The homogenates were centrifuged at 13,000 3 g for 20 min at 4 °C.
Supernatants were transferred to the new tubes, and protein concen-
tration was determined by Bradford assay (Bio-Rad). Quinone reduc-
tase activity was determined by measuring the reduction of 2,6-di-
chloroindophenol (36). Approximately 5 mg of total cytosolic protein was
added to the cuvette containing 1 ml of assay buffer (25 mM Tris-HCl,
pH 7.4, 60 mg bovine serum albumin, 5 mM FAD, 0.2 mM NADH, 80 mM
2, 6-dichloroindophenol, and 0.01% Tween 20). Reaction was performed
for 5 min at room temperature and terminated with 30 mM dicumarol.
The absorbance of reaction mixture at 600 nm was read on a spectro-
photometer, and QR activity was expressed as nmol of 2,6-dichloroin-
dophenol reduced per min per mg of protein.
Western Blotting—Cell lysates were prepared as described in immu-
nocomplex kinase assays. 25 mg of protein was resolved with 10%
SDS-polyacrylamide gel electrophoresis and transferred to polyvinyli-
dene difuoride membrane using a semi-dry transfer system (Fisher).
Membrane was blocked with 5% nonfat dry milk in Tris-buffered saline
containing 20 mM Tris-HCl, pH 7.4, 8 g/liter NaCl, and 0.2 g/liter KCl
for 1 h at room temperature, followed by incubation with 1 mg/ml
primary antibodies in Tris-buffered saline overnight at 4 °C. Membrane
was washed three times with Tris-buffered saline and blotted with
horseradish peroxidase-conjugated secondary antibodies for 1 h at room
temperature. Membrane was again washed three times with Tris-buff-
ered saline and analyzed by the ECL system (Amersham Pharmacia
Biotech).
RESULTS
SUL and tBHQ Stimulate ERK2 Activity in Human HepG2
and Mouse Hepa1c1c7 Hepatoma Cell Lines—In the previous
studies, we have shown that tBHQ induced ERK2 activity in a
time- and dose-dependent manner in HepG2 cells (37). To
study the activation of ERK2 by SUL, we treated HepG2 cells
with various concentrations of SUL. The endogenous ERK2
activity was determined by in vitro immunocomplex kinase
assays. As shown in Fig. 1A, ERK2 activity began to increase at
5 mM of SUL. A maximal activity (approximately 8-fold over the
control cells) was seen at 50 mM. The stimulated ERK2 activity
began to decline when the concentration of SUL reached 100
mM, indicating that ERK2 activation by SUL was a dose-de-
pendent event. The decreased ERK2 activation at relative high
concentrations of SUL, such 100 mM, seemed not due to the
MAP Kinases and Induction of Detoxifying Enzymes27546
toxic effect of this compound, because no morphological change
or cell death was observed when ERK2 activity was measured
(data not shown).
ERK2 activation by SUL in HepG2 cells was also time-de-
pendent (Fig. 1B). The induced ERK2 activity appeared at 30
min, reached the maximum between 1 and 2 h after treatment
with SUL, and then declined. Interestingly, the time course of
ERK2 activation by SUL was very similar to that of ERK2
activation by tBHQ (37), suggesting that two inducers may
regulate ERK2 activity through a common pathway. When
Western blotting was performed, no change in the protein level
of ERK2 was observed throughout the dose response as well as
time course studies (Fig. 1, A and B), indicating that the in-
duction of ERK2 activity resulted from the phosphorylation of
pre-existing ERK2 molecules rather than de novo protein
synthesis.
We also examined ERK2 activation in Hepa1c1c7 cells,
which, like HepG2 cells, have been widely used for the study of
phase II enzyme induction (38). As shown in Fig. 1C, both SUL
and tBHQ stimulated ERK2 activity. The activation of ERK2
was dose-dependent, with a maximal activity seen at 25 mM of
SUL or at 100 mM of tBHQ.
SUL Does Not Stimulate JNK Activity and Instead Inhibits
UVC- and Anisomycin-induced JNK Activation—After demon-
stration of ERK2 activation, we examined the involvement of
JNK1, another member of MAPK family. As shown in Fig. 2A,
SUL did not stimulate JNK1 activity; instead, relatively high
concentrations of SUL reduced the JNK1 activity to the levels
much lower than that seen in control cells (0.1% Me2SO-treated
cells). Furthermore, SUL, at concentrations that induced ERK2
activity, inhibited JNK1 activation by UVC and anisomycin
(Fig. 2B). These results, together with our previous observation
that tBHQ weakly stimulated JNK1 activity in HepG2 cells
(37), suggest that the JNK pathway may not be involved or at
least are not essential in tBHQ- or SUL-induced cell signaling
that leads to the induction of gene expression.
ERK2 Activation by tBHQ and SUL Is MEK-dependent—We
have previously shown that ERK2 activation by tBHQ requires
the involvement of an upstream signaling kinase MAPK/ERK
kinase (MEK) (37). To determine whether ERK2 activation by
SUL also requires MEK, we measured the MEK activity in
SUL-treated HepG2 cells using an inactive kinase
ERK2(K52R) as substrate. As shown in Fig. 3A, SUL stimu-
lated phosphorylation of K52R in a dose-dependent manner
similar to that seen in ERK2 activity assay. This result indi-
cates that MEK was activated in the cells treated with SUL.
To provide further evidence for the involvement of MEK in
ERK2 activation by SUL, we took advantage of a recently
identified specific MEK inhibitor, PD98059 (39). In solvent
(0.1% Me2SO)-pretreated HepG2 cells, SUL strongly induced
ERK2 activity; however, preincubation with 25 mM or 50 mM
PD98059 completely blocked SUL activation of ERK2 (Fig. 3B).
PD98059 alone had no detectable effect on ERK2 activity com-
pared with the control cells. In Hepa1c1c7 cells, PD98059 also
blocked ERK2 activation by SUL (Fig. 3C). Taken together,
these data demonstrate that SUL, like tBHQ, induced MEK-
dependent activation of ERK2.
Inhibition of ERK2 Activation Attenuates the Induction of
Quinone Reductase Activity by tBHQ and SUL—tBHQ and
SUL induce many phase II detoxifying enzymes, such as GST,
QR, and UDP-glucuronosyl transferase-glucuronosyltrans-
ferase. Experiments with Hepa1c1c7 cells showed that QR
induction is a useful indicator of overall phase II enzyme in-
duction (15, 41, 42). To provide first evidence for the involve-
ment of ERK2 pathway in the regulation of phase II enzyme
induction by SUL and tBHQ, we examined the effect of
PD98059 on QR activity induced by tBHQ and SUL in
Hepa1c1c7 cells. As shown in Fig. 4, tBHQ (50 mM) and SUL
(12.5 mM) significantly stimulated QR activity. Pretreatment
with PD98059 caused a dose-dependent inhibition of tBHQ-
and SUL-induced QR activity. However, PD98059 alone only
slightly decreased the basal QR activity. These data suggest
that the induction of phase II detoxifying enzymes by tBHQ
FIG. 1. Activation of ERK2 by SUL and tBHQ. A, dose response of
ERK2 activation by SUL. After overnight serum starvation, HepG2
cells were treated either with different concentrations of SUL for 1 h or
with 0.1% Me2SO as control. The endogenous ERK2 activity was deter-
mined by immunocomplex kinase assays as described under “Materials
and Methods” with MBP as substrate. The protein level of ERK2 was
determined by Western blotting. B, time course of ERK2 activation by
SUL. HepG2 cells were either treated with 0.1% Me2SO as control or
with 25 mM SUL for different times as indicated. ERK2 activity and
protein level were determined as in A. C, dose-dependent activation of
ERK2 by SUL and tBHQ in Hepa1c1c7 cells. After treatment for 1 h
with different concentrations of SUL or tBHQ, cells were harvested for
ERK2 activity assay as in A. The data presented are the means of three
independent experiments.
FIG. 2. Effect of SUL on JNK1 activity. A, dose-dependent effect of
SUL on JNK1 activity. Serum-starved HepG2 cells were treated with
various concentrations of SUL for 2 h and harvested. JNK1 activity was
determined by immunocomplex kinase assays with GST-c-Jun (1–79) as
substrate. B, dose-dependent inhibition of UVC- or anisomycin-induced
JNK1 activity by SUL. Serum-starved HepG2 cells were pretreated
with the indicated concentrations of SUL for 1 h before stimulation with
UVC (80 J/m2) or 10 mg/ml of anisomycin (ANI) for 30 min. Cells were
harvested and assayed for JNK1 activity as in A. The experiment was
repeated for three times.
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and SUL may be regulated by an ERK-dependent mechanism.
Inhibition of ERK2 Activation Diminishes the Induction of
ARE-dependent CAT Activity by tBHQ and SUL—Previous
studies have shown that the induction of phase II detoxifying
enzymes by tBHQ and SUL is mediated by ARE (17, 18, 41, 43).
Thus, we decided to examine whether the inhibitory effect of
PD98059 on tBHQ- or SUL-induced QR activity was due to the
inhibition of ARE-mediated gene expression. HepG2 cells were
transiently transfected with a plasmid construct containing a
single copy of 41-base pair ARE enhancer linked to the GST Ya
minimal promoter (base pairs 2164 to 166)-CAT gene. Expo-
sure of transfected HepG2 cells to 25 mM SUL caused a time-
dependent induction of CAT activity (Fig. 5A). The induced
CAT activity was seen as early as 4 h, immediately following
the peak of ERK2 activation (Fig. 2B). Pretreatment with
PD98059 (25 mM) substantially reduced the induction of re-
porter gene activity by SUL (Fig. 5A). tBHQ (100 mM) also
strongly induced CAT activity, which was inhibited by
PD98059 in a dose-dependent manner (Fig. 5B). PD98059
alone only slightly decreased CAT activity as compared with
the control cells (treated with 0.1% Me2SO). When the cells
transfected with a CAT construct containing GST Ya minimal
promoter but lacking ARE enhancer were stimulated with SUL
or tBHQ, no induction of CAT activity was observed (Fig. 5C).
These data provide strong evidence for the role of ERK2 path-
way in ARE-mediated phase II enzyme induction by SUL and
tBHQ.
Interestingly, SUL-stimulated ERK2 activity was transient,
peaking at 90 min (Fig. 1B), whereas the stimulated ARE
reporter gene activity was prolonged and continued to increase
even up to 24 h after stimulation with SUL (Fig. 5A). Although
the exact reasons for such a lasting induction are not clear, it is
possible that ERK2 activity may be only required for the initi-
ation of downstream signals that are responsible for induction
of ARE-dependent gene expression. Another interesting obser-
vation is that PD98059 inhibited the induction of ARE reporter
gene in a time-dependent fashion. PD98059 almost completely
blocked the induction of ARE activity at 4 and 8 h; however, it
only partially inhibited the induction at later time points (12
and 24 h). Given that PD98059 at 25 mM exhibited similar
inhibitory effect on ERK activation as higher concentration of
50 mM (Fig. 3, B and C) but showed less inhibition on ARE
inhibitory (Fig. 5B), we speculate that a weak ERK activation
(in the presence of 25 mM PD98059) may be undetectable in our
system, but it sufficed to amplify the downstream effectors,
contributing to such an incomplete inhibition by PD98059.
Alternatively, a prolonged treatment with SUL or tBHQ may
generate a second signaling event that leads to ERK-independ-
ent activation of ARE reporter gene, which could also contrib-
ute to the sustained induction as seen in this study.
Overexpression of a Dominant-negative Mutant of ERK2 Im-
pairs ARE-mediated Induction of Luciferase Activity by SUL
and tBHQ—To corroborate our experiment, we examined the
effect of overexpression of a dominant-negative mutant of
ERK2 on SUL- and tBHQ-induced ARE-luciferase reporter
gene activity. To do so, we first tested the inducible activity of
ARE-luciferase reporter gene by SUL and tBHQ. HepG2 cells
were either transfected with ARE-linked luciferase reporter
construct (ARE-TI-Luc) or with the construct (TI-Luc) that
lacks ARE enhancer. After transfection, cells were exposed to
SUL or tBHQ for 24 h, and the luciferase activity was assayed
as described under “Materials and Methods.” As shown in Fig.
6A, both SUL and tBHQ strongly induced luciferase activity in
HepG2 cells transfected with ARE-TI-Luc construct but not in
the cells transfected with the TI-Luc construct. Furthermore, a
much lower basal luciferase activity was observed in TI-Luc-
transfected cells than that in ARE-TI-Luc-transfected cells.
Thus, consistent with the previous results, ARE is a regulatory
sequence responsible for the high basal as well as the inducible
activities of phase II enzymes. Co-transfection of ARE-lucif-
erase reporter with a dominant-negative ERK2 mutant,
FIG. 3. MEK-dependent activation of ERK2 by SUL. A, activa-
tion of MEK by SUL. Serum-starved HepG2 cells were either treated
with various concentrations of SUL or with 0.1% Me2SO (Control) for
1 h. MEK activity was determined by the phosphorylation of a kinase
inactive ERK2 mutant protein p42MAPK as described under “Materials
and Methods.” B, blockade of SUL-induced ERK2 activity by a MEK
inhibitor, PD98059, in HepG2 cells. Serum-starved HepG2 cells were
pretreated with the indicated concentrations of PD98059 for 1 h before
exposure to 25 mM SUL for an additional 1 h. ERK2 activity was
determined using MBP as a substrate. C, blockade of SUL-induced
ERK2 activity by a MEK inhibitor, PD98059, in Hepa1c1c7 cells. Se-
rum-starved Hepa1c1c7 cells were pretreated with PD98059 prior to
stimulation with SUL as in B. Cells were then harvested for ERK2
activity assay. Similar results were obtained in at least three different
experiments.
FIG. 4. Inhibition of SUL- and tBHQ-induced QR activity by
PD98059. Hepa1c1c7 cells were either pretreated with vehicle (0.1%
Me2SO) or with the indicated concentrations of PD98059 for 1 h, prior
to incubation with 12.5 mM SUL or 50 mM tBHQ for 24 h in the continu-
ing presence of PD98059. Cells were harvested and assayed for the QR
activity as described under “Materials and Methods.” The data pre-
sented are averages of four independent experiments.
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FIG. 5. Inhibition of SUL- and tBHQ-stimulated transcription
of an ARE-CAT reporter gene by PD98059. A, HepG2 cells were
transfected with 0.5 mg of pCH110-b-galactosidase plasmid and 1.5 mg
of ARE-CAT reporter construct overnight. Transfected cells were then
cultured in fresh medium containing 0.5% fetal bovine serum for 12 h
and pretreated with 25 mM PD98059 or with the vehicle (0.1% Me2SO)
for 1 h, followed by exposure to 25 mM SUL for different times. CAT
activity was determined as described under “Materials and Methods”
and was normalized against b-galactosidase activity. The amount of
CAT activity in the cells treated with vehicle alone for 24 h, as shown in
lane C, was normalized to 1. B, HepG2 cells were transfected as in A.
The transfected cells were either pretreated with the indicated concen-
trations of PD98059 or with the vehicle for 1 h and then exposed to 100
mM tBHQ for 24 h or left untreated. CAT activity was determined and
normalized as described above. C, HepG2 cells were transfected with
0.5 mg of pCH110-b-galactosidase plasmid plus 1.5 mg of plasmid con-
taining only minimal GST-Ya promoter linked to CAT gene. The trans-
fected cells were treated with 25 mM SUL or 100 mM tBHQ for 24 h and
harvested for CAT activity assay. The data presented are averages of
three independent experiments done in duplicate.
FIG. 6. Effects of a dominant-negative mutant of ERK2 on the
activation of ARE-luciferase reporter gene and ERK2 by SUL
and tBHQ. A, HepG2 cells were transfected with 0.5 mg of plasmid
carrying ARE enhancer and synthetic TI-promoter linked to luciferase
reporter gene (ARE-Luc) or with the reporter construct without ARE
(TI-Luc). The plasmid (0.5 mg) encoding b-galactosidase was included as
internal control of transfection efficiency. Transfected cells were treated
25 mM SUL or 100 mM tBHQ for 24 or left untreated as control. Lucif-
erase activity was determined and normalized as described under “Ma-
terials and Methods.” B, HepG2 cells were transfected with 0.5 mg of
ARE-luciferase reporter plasmid, 0.5 mg of pCH110-b-galactosidase,
and different amount of either empty expression vector or the expres-
sion vector for a dominant-negative mutant of ERK2, ERK2(KR).
Transfected cells were then treated as in A and harvested for luciferase
activity assay. The amount of luciferase activity in the cells transfected
with empty expression vector and treated with SUL or tBHQ was
arbitrarily set to 100%. C, HepG2 cells were transfected with 1 mg of
HA-tagged ERK2 plasmid plus different amount of expression vector for
dominant-negative mutant, ERK2(KR). Transfected cells were then
treated with SUL (25 mM) or with tBHQ (100 mM) for 1 h. The exogenous
ERK2 was immunoprecipitated with anti-HA monoclonal antibody
(12CA5) and assayed for kinase activity using MBP as substrate. The
data presented are averages of three independent experiments done in
duplicate.
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ERK2(KR), significantly decreased the luciferase activity in-
duced by SUL (25 mM) and tBHQ (100 mM) in a dose-dependent
manner but had little effect on the basal activity (Fig. 6B).
Overexpression of ERK2(KR) also significantly reduced SUL
and tBHQ activation of ERK2 in a dose-dependent manner
similar to that in luciferase assays (Fig. 6C). Therefore, these
data substantiate the role or ERK2 pathway in the induction of
ARE-dependent gene expression. Interestingly, ERK2(KR) also
showed partial inhibition on tBHQ- and SUL-induced ARE
activity (Fig. 6B). This could be due to the incomplete inhibition
of ERK activity in ERK2(KR)-expressing cells as shown in Fig.
6C, although we cannot exclude the possibility that an ERK-
independent pathway may exist in regulating ARE-dependent
gene expression as discussed earlier.
Activation of ERK2 Pathway by tBHQ and SUL Is Independ-
ent of Ras but May Directly Involve Raf-1—Previous studies
have shown that Ras is a most common upstream regulator of
ERK pathway (3, 9). We therefore examined the role of Ras in
tBHQ- and SUL-induced ERK2 activation and Phase II gene
expression. As shown in Fig. 7A, overexpression of wild type
Ras or an active form of Ras, Ras(61L), stimulated ARE-de-
pendent luciferase activity and ERK2 activity, whereas a dom-
inant-negative mutant of Ras, Ras(17N), showed the opposite
effect. The activation of ARE reporter gene and ERK2 by Ras or
its active form was also inhibitable by PD98059 (Fig. 7A).
These results substantiate the role of ERK pathway in phase II
gene induction. However, expression of dominant-negative
Ras(17N) mutant had little effect on tBHQ- and SUL-stimu-
lated ERK2 activity (Fig. 7B). Consistent with this observation,
overexpression of Ras, Ras(61L), or Ras(17N) did not cause
significant changes in the fold of induction of ARE reporter
gene activity by tBHQ or SUL (Fig. 7C). These results suggest
that tBHQ and SUL may activate ERK2 pathway through the
component independent or downstream of Ras. Accordingly, we
examined the role of Raf-1. Treatment of HepG2 cells with
tBHQ or SUL stimulated Raf-1 activity, as determined by
immunocomplex assays (Fig. 7D). More interestingly, direct
incubation of tBHQ or SUL with immunoprecipitated Raf-1
also stimulated kinase activity of Raf-1 (Fig. 7E). This result
suggests that tBHQ and SUL may directly act on Raf-1, result-
ing in MEK-dependent activation of ERK2 pathway.
DISCUSSION
MAPK cascades are the most conserved of signal transduc-
tion systems in all eucaryotes and have been shown to partic-
ipate in cell differentiation, cell division, cell movement, and
cell death (44). In this study, we found that treatment of HepG2
and Hepa1c1c7 cells with phase II detoxifying enzyme inducers
FIG. 7. The roles of Ras and Raf-1 in the activation of ERK2
and ARE reporter gene by tBHQ and SUL. A, HepG2 cells were
transfected with 0.5 mg of ARE-luciferase reporter construct, 0.5 mg of
b-galactosidase plasmid, and either 1 mg of empty vector or the plas-
mids encoding wild type Ras(WT), activated Ras(61L), or dominant-
negative Ras(17N) in the presence or absence of 25 mM PD98059. Cells
were harvested 24 h after transfection and assayed for luciferase activ-
ity. For ERK2 activity assay, HepG2 cells were transfected 1 mg of
HA-tagged ERK2 plasmid plus 1 mg of expression vectors for Ras,
Ras(61L), or Ras(17N) in the presence or absence of PD98059. Exoge-
nous ERK2 was immunoprecipitated with anti-HA monoclonal anti-
body (12CA5) 24 h after transfection and assayed for kinase activity
using MBP as substrate. B, HepG2 cells were transfected 1 mg of
HA-tagged ERK2 plasmid plus 1 mg of expression vector for Ras(17N) or
empty vector. 24 h after transfection, cells were treated with 25 mM SUL
or 100 mM tBHQ for 1 h. Exogenous ERK2 was immunoprecipitated and
assayed for kinase activity as in A. C, HepG2 cells were transfected as
in A. After transfection, cells were either treated with 25 mM SUL or 100
mM tBHQ for 24 h or left untreated as control and then harvested for
luciferase activity assay. The fold induction was calculated by using the
cells transfected the corresponding vector but untreated as control. D,
HepG2 cells were treated with SUL (25 mM) or tBHQ (100 mM) for
different times. Raf-1 was immunoprecipitated with polyclonal anti-
Raf-1 antibody and assayed for kinase activity using MEK fusion pro-
tein as substrate. The protein level of Raf-1 was determined by Western
blotting. E, Raf-1 was first immunoprecipitated from untreated cells
with anti-Raf-1 antibody and then incubated with different concentra-
tions of tBHQ or SUL in a 30-ml kinase assay buffer for 30 min. Raf-1
kinase activity was measured by the phosphorylation of MEK fusion
protein as in D. The data presented are averages or examples of three
independent experiments.
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tBHQ and SUL caused activation of ERK2 kinase pathway.
Inhibition of ERK2 activation by a specific MEK inhibitor,
PD98059, impaired the induction of QR activity as well as the
activation ARE-dependent reporter gene by tBHQ and SUL.
Consistent with this, blockade of ERK2 signaling by overex-
pressing a dominant-negative mutant of ERK2, ERK2(KR),
also attenuated the induction of ARE-dependent reporter gene
activity by the inducers. Thus, this study demonstrated for the
first time that ERK kinase pathway also participates in the
ARE-mediated induction of phase II detoxifying enzymes.
An earlier study suggested a role of protein phosphorylation
in the activation of phase II genes (30). For example, okadaic
acid, a potent inhibitor of serine/threonine protein phophata-
ses, mimics many phase II enzyme inducers to strongly stim-
ulate ARE-dependent Ya-CAT activity, whereas genistein, a
protein tyrosine kinase inhibitor, blocks the activation of ARE-
dependent reporter gene by tBHQ, b-naphthoflavone, and
3-methycholathrene. The present study shows that such a role
of protein phosphorylation is, perhaps, mediated by ERK2 ki-
nase pathway. Unlike ERK2, however, no detectable JNK1
activation was observed in tBHQ- or SUL-treated cells. In fact,
pretreatment with SUL inhibited JNK1 activation by UVC and
anisomycin. Thus, JNK1 does not seem to play a role in the
phase II enzyme induction by tBHQ- and SUL. In an independ-
ent study, we found that treatment with several phase II en-
zyme inducers, including tBHQ, also activated p38, another
member of MAPK family. Inhibition of p38 activation by a
specific p38 inhibitor, SB203580, potentiated the activation of
ARE-dependent reporter gene,2 indicative of a negative role of
p38 MAPK. It is therefore conceivable that the induction of
phase II detoxifying enzymes can be either positively or nega-
tively regulated by protein phosphorylation and may involve
the differential roles of the members of MAPK family.
MAPK are ubiquitously activated, but the mechanisms by
which they are activated by membrane-associated upstream
components vary with the cell type and stimulator, and the
effectors to which they are connected likewise vary. This pro-
vides the basis of specificity, and it is important to understand
the contextual diversity of the signaling. Activation of ERK
pathway in response to many stimuli such growth factors and
oxidative stresses has been shown to be regulated by a small
GTPase, Ras (1, 3, 10, 11). In this study, we show that expres-
sion of wild type or activated form of Ras leads to the activation
of ERK2 and ARE-dependent reporter gene, whereas domi-
nant-negative mutant Ras(17N) shows the inhibitory effect.
These data support the role of ERK pathway in the induction of
phase II detoxifying enzymes. However, overexpression of dif-
ferent forms of Ras does not alter the fold of induction of ARE
reporter gene activity by tBHQ and SUL. Furthermore, forced
expression of dominant-negative mutant Ras(17N) has little
effect on the activation of ERK2 by tBHQ and SUL, suggesting
that tBHQ and SUL may activate ERK pathway through the
components independent or downstream of Ras. Indeed, our
results indicate that tBHQ and SUL may directly act on Raf-1,
an immediate downstream effector of Ras, leading to the acti-
vation of ERK2, because incubation of tBHQ or SUL with the
immunoprecipitated Raf-1 results in elevation of Raf-1 kinase
activity. SUL contains an isothiocyanate group that has been
shown to actively modify many proteins through the sulfhydryl
groups (45). It is therefore conceivable that activation of Raf-1
may be a consequence of direct interaction of SUL and Raf-1
molecules. Unlike SUL, tBHQ may activate Raf-1 in an indirect
way, probably by generation of phenoxyl free radicals, which
has been previously implicated in ERK2 activation by BHA and
tBHQ (37). However, the precise mechanisms by which Raf-1 is
activated by tBHQ and SUL remain to be elucidated.
Activated ERK2 can phosphorylate several cytosolic and nu-
clear proteins, including ternary complex factor, Elk-1 (46).
Phosphorylation of Elk-1 enhances its interaction with the
serum response factors at the c-fos promoter, resulting in the
induction of c-Fos, which, in turn, activates AP-1-dependent
genes (12). However, the role of AP-1 in ARE-mediated activa-
tion of phase II genes remains controversial (23, 24, 27, 28, 30,
47). Besides, we did not observe any significant effect of a
dominant-negative mutant of c-Jun, Tam-67, on the activation
of ARE reporter gene by tBHQ and SUL (data not shown).
Thus, search for the new targets of ERK2 kinase is warranted.
Recently, several novel ARE-binding proteins have been iden-
tified, including the members of basic leucine zipper transcrip-
tion (bZIP) factor family, Nrf1(47), Nrf2 (47, 48), and Maf (48).
A novel nuclear protein, designated as ARE-BP-1, has also
been described to constitutively bind to the ARE-inducible se-
quence, the GC box, and to be activated by tBHQ through a
post-translational mechanism (49). It will be interesting to
examine whether the transcription activities of these ARE-
binding proteins can be regulated by ERK pathway. Most re-
cently, a cytosolic protein, named Keap1, has been identified to
suppress Nrf2 transcriptional activity by retaining Nrf2 in the
cytoplasm (40). Thus, it is tempting to speculate that activation
of ERK pathway may lead to the phosphorylation of Keap1 and
the release of Nrf2 from Keap1-Nrf2 complex, resulting in
nuclear translocation of Nrf2 and activation of ARE-dependent
genes.
In summary, we have identified a signal transduction path-
way that mediates the induction of ARE-dependent phase II
gene expression by tBHQ and SUL. This finding advances our
understanding of the regulatory mechanisms of chemical-in-
duced phase II gene expression. Given that phase II detoxifying
enzymes are induced by a variety of compounds, multiple sig-
naling pathways may exist. A future challenge is to elucidate
how ERK kinase integrates with other signaling pathways to
mediate the action of various phase II enzyme inducers.
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